JPH0423968A - Composition for food - Google Patents
Composition for foodInfo
- Publication number
- JPH0423968A JPH0423968A JP2125544A JP12554490A JPH0423968A JP H0423968 A JPH0423968 A JP H0423968A JP 2125544 A JP2125544 A JP 2125544A JP 12554490 A JP12554490 A JP 12554490A JP H0423968 A JPH0423968 A JP H0423968A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- water
- dietary fiber
- food composition
- soluble dietary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 235000013305 food Nutrition 0.000 title claims abstract description 38
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 36
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000011575 calcium Substances 0.000 claims abstract description 33
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 33
- 229940043430 calcium compound Drugs 0.000 claims abstract description 26
- 150000001674 calcium compounds Chemical class 0.000 claims abstract description 26
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 18
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 13
- 230000007935 neutral effect Effects 0.000 claims abstract description 10
- 108010000912 Egg Proteins Chemical group 0.000 claims abstract description 7
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 7
- 210000003278 egg shell Anatomy 0.000 claims abstract description 7
- 241000251468 Actinopterygii Species 0.000 claims abstract description 6
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 4
- 229960001126 alginic acid Drugs 0.000 claims abstract description 4
- 239000000783 alginic acid Substances 0.000 claims abstract description 4
- 229920000615 alginic acid Polymers 0.000 claims abstract description 4
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 210000004051 gastric juice Anatomy 0.000 claims abstract description 3
- 235000013325 dietary fiber Nutrition 0.000 claims description 32
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 10
- 235000015278 beef Nutrition 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 29
- 239000008103 glucose Substances 0.000 abstract description 29
- 239000000835 fiber Substances 0.000 abstract description 5
- 235000019789 appetite Nutrition 0.000 abstract description 2
- 230000036528 appetite Effects 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 24
- 235000010413 sodium alginate Nutrition 0.000 description 21
- 239000000661 sodium alginate Substances 0.000 description 21
- 229940005550 sodium alginate Drugs 0.000 description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 20
- 210000002784 stomach Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 235000003642 hunger Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920002148 Gellan gum Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 235000010492 gellan gum Nutrition 0.000 description 4
- 239000000216 gellan gum Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、食品用組成物に関する。本廃明の食品用組成
物は、空腹感を軽減し、摂食量を減少させることを目的
とするもので、たとえば肥満の予防および治療時の減食
療法などのほか、飲食後栄養素の吸収を遅延させて血液
成分の急激な変化を避け、結果として耐糖能を改善しイ
ンスリンの分泌を抑制する目的で糖尿病患者なと耐糖能
の低下している者および耐糖能の低下を予防したい者の
食事に配合し使用される。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a food composition. This food composition is aimed at alleviating hunger and reducing the amount of food intake, and can be used, for example, in diet reduction therapy during the prevention and treatment of obesity, as well as by delaying the absorption of nutrients after eating and drinking. In order to avoid sudden changes in blood components, and as a result improve glucose tolerance and suppress insulin secretion, it is recommended for use in the diet of diabetic patients, people with decreased glucose tolerance, and those who want to prevent decreased glucose tolerance. It is mixed and used.
〔従来の技術および発明が解決しようとする課題〕飽食
の時代と言われる今日、肥満症の増加は重大な社会問題
となりつつある。疫学的な調査からも肥満者では、糖尿
病、高血圧、心臓病なとの成人病の発生率が高いことな
ども報告されている。[Problems to be solved by conventional techniques and inventions] In today's era, which is said to be an age of satiation, the increase in obesity is becoming a serious social problem. Epidemiological studies have also reported that obese people have a higher incidence of adult diseases such as diabetes, hypertension, and heart disease.
肥満症の大部分は摂取カロリーの過剰に起因している。Most obesity is caused by excessive calorie intake.
従って、その予防や治療の基本は、摂取カロリーを低減
すること、すなわち減食療法を実施することである。減
食療法の実施における最大の障害は強い空腹感のために
継続が困難となることである。空腹感を形成する要因と
しては、血糖値の低下、血中遊離脂肪酸やケトン体の上
昇などがある。また、胃に対する機械的伸展刺激が、空
腹感を軽減することも古くから経験的に知られている。Therefore, the basis of its prevention and treatment is to reduce calorie intake, that is, to implement a diet regimen. The biggest obstacle in implementing reduced eating therapy is that it is difficult to continue it due to strong feelings of hunger. Factors that create a feeling of hunger include a decrease in blood sugar levels and an increase in blood free fatty acids and ketone bodies. It has also been empirically known for a long time that mechanical stretching stimulation of the stomach reduces hunger.
これを利用して空腹感を軽減する目的でカロリーが低く
、かさの多い食物繊維を食品に配合するなどの工夫がな
されてきた。食物繊維によって持続的に空腹感を軽減す
るためには、食物繊維が長時間胃内に滞留することが必
要である。食物繊維の胃内滞留時間は、その粘度と相関
が高いと言われている。従って、空腹感の軽減効果を高
めるためには、より高粘度の食品を摂取する必要があり
、嗜”好上の困難があった。To take advantage of this, efforts have been made to incorporate low-calorie, high-bulk dietary fiber into foods to reduce hunger. In order for dietary fiber to continuously reduce hunger, it is necessary for dietary fiber to remain in the stomach for a long time. It is said that the residence time of dietary fiber in the stomach is highly correlated with its viscosity. Therefore, in order to enhance the effect of reducing hunger, it is necessary to ingest foods with higher viscosity, which poses problems in terms of taste.
また、昨今の研究から食物繊維には脂質代謝改善作用や
耐糖能改善作用があることも報告されている。耐糖能改
善作用もまた空腹感の軽減作用と同様、粘度と相関が高
いと言われている。一方、食物繊維の大量摂取には、ミ
ネラルやビタミンなどの微量栄養素の吸収阻害などの負
の効果が懸念されている。従って、いかに少量の食物繊
維で空腹感の軽減や耐糖能改善作用を発現させるかが最
大の課題である。このような考えに基づいた提案がなさ
れている(特開昭63−185339)。Furthermore, recent research has reported that dietary fiber has lipid metabolism-improving effects and glucose tolerance-improving effects. The glucose tolerance-improving effect is also said to be highly correlated with viscosity, as is the hunger-reducing effect. On the other hand, there are concerns that consuming large amounts of dietary fiber may have negative effects such as inhibiting the absorption of micronutrients such as minerals and vitamins. Therefore, the biggest challenge is how to reduce hunger and improve glucose tolerance with a small amount of dietary fiber. A proposal has been made based on this idea (Japanese Unexamined Patent Publication No. 185339/1983).
この発明は、カゼインとカラギナンなどの蛋白と反応性
を有する水溶性食物繊維を組合せ、この組成物がpHの
低下に伴いゲルを形成する特性を利用し、胃内でゲルを
形成させようとするものである。This invention combines water-soluble dietary fibers that are reactive with proteins such as casein and carrageenan, and utilizes the property of this composition to form a gel as the pH decreases to form a gel in the stomach. It is something.
しかし、この組成物は粘度が温度に依存性の高い食物繊
維を用いているため、低温では粘度が高くなり、食感が
著しく損なわれる。そのため、この組成物はスープのご
とき高温で摂取される食品に用途が限定されていた。ま
た、カゼインが変性するような高温などの条件下でこの
組成物を含有する食品を加工することはできなかった。However, since this composition uses dietary fiber whose viscosity is highly dependent on temperature, the viscosity increases at low temperatures and the texture is significantly impaired. Therefore, the use of this composition has been limited to foods that are consumed at high temperatures, such as soups. Also, it has not been possible to process foods containing this composition under conditions such as high temperatures that would denature the casein.
本発明の第1の目的は、胃内滞留時間が著しく長く、低
温でも食感が損なわれることなく、かつ嗜好性に優れ、
しかも摂取の不足が指摘されている食物繊維とカルシウ
ムを含有する肥満の治療または予防に使用される食品用
組成物を提供することにある。The first object of the present invention is to have an extremely long gastric residence time, maintain its texture even at low temperatures, and have excellent palatability.
Moreover, it is an object of the present invention to provide a food composition that can be used to treat or prevent obesity and contains dietary fiber and calcium, which have been shown to be insufficient in intake.
本発明の第2の目的は、耐糖能が低下した者の血糖値の
急激な上昇を抑えインスリンの過剰分泌を抑制させる食
品用組成物を提供することにある。A second object of the present invention is to provide a food composition that suppresses rapid increases in blood sugar levels in people with impaired glucose tolerance and suppresses excessive secretion of insulin.
かかる目的は下記の構成を有する本発明の食品用組成物
によって達成される。This object is achieved by the food composition of the present invention having the following structure.
(1)水溶性食物繊維と中性領域で不溶性のカルシウム
化合物を含有する組成物からなり、該水溶性食物繊維と
該カルシウム化合物の水溶液が胃液と接触した際にゲル
状となるような割合であることを特徴とする食品用組成
物。(1) A composition comprising water-soluble dietary fiber and an insoluble calcium compound in a neutral range, in a ratio such that an aqueous solution of the water-soluble dietary fiber and the calcium compound becomes gel-like when it comes into contact with gastric juice. A food composition characterized in that:
(2)水溶性食物繊維が、アルギン酸またはその塩であ
る請求項1記載の食品用組成物。(2) The food composition according to claim 1, wherein the water-soluble dietary fiber is alginic acid or a salt thereof.
(3) カルシウム化合物が炭酸カルシウム、第3燐
酸カルシウム、卵殻カルシウム、牛骨カルシウムおよび
魚骨カルシウムから選ばれた1種または2種以上の組合
せである請求項1記載の食品用組成物。(3) The food composition according to claim 1, wherein the calcium compound is one or a combination of two or more selected from calcium carbonate, tertiary calcium phosphate, eggshell calcium, beef bone calcium, and fish bone calcium.
(4)水溶性食物繊維とカルシウム化合物中のカルシウ
ムとの重量比が1:0.1〜1:10である請求項1記
載の食品用組成物。(4) The food composition according to claim 1, wherein the weight ratio of water-soluble dietary fiber to calcium in the calcium compound is 1:0.1 to 1:10.
(5)水溶性食物繊維とカルシウム化合物中のカルシウ
ムとの重量比がl:0.5〜1:2である請求項1記載
の食品用組成物。(5) The food composition according to claim 1, wherein the weight ratio of water-soluble dietary fiber to calcium in the calcium compound is 1:0.5 to 1:2.
以下に本発明の食品用組成物について詳しく説明する。The food composition of the present invention will be explained in detail below.
水溶性食物繊維としては各種のものを使用できるが、ア
ルギン酸またはその塩、例えばアルギン酸ナトリウム、
アルギン酸カリウムなどが好適である。また、カルシウ
ム化合物としては炭酸カルシウム、第3燐酸カルシウム
、卵殻カルシウム。Various types of water-soluble dietary fiber can be used, including alginic acid or its salts, such as sodium alginate,
Potassium alginate and the like are suitable. Calcium compounds include calcium carbonate, tertiary calcium phosphate, and eggshell calcium.
牛骨カルシウム、魚骨カルシウムなどが好ましいもので
あり、これらを単独で、もしくは2種以上を組合せて用
いる。これらのカルシウム化合物は中性領域では不溶性
もしくはほとんど溶解せず、従って、中性の溶液状で該
水溶性食物繊維と混合しても、この時点ではゲル化しな
い。さらに、水溶性食物繊維とカルシウム化合物中のカ
ルシウムとの重量比が1:0.1〜1:10である。カ
ルシウム化合物中のカルシウムの水溶性食物繊維に対す
る重量が0.01倍以下の場合には、胃酸によりカルシ
ウム化合物が全て溶解しても十分なゲル化は起こらない
。一方、カルシウム化合物中のカルシウムの水溶性食物
繊維に対する重量が8倍以上の場合にはカルシウム化合
物のざらつき惑が生じ、嗜好性が低下する。Beef bone calcium, fish bone calcium, and the like are preferred, and these may be used alone or in combination of two or more. These calcium compounds are insoluble or barely soluble in a neutral region, and therefore, even when mixed with the water-soluble dietary fiber in the form of a neutral solution, they do not gel at this point. Furthermore, the weight ratio of water-soluble dietary fiber to calcium in the calcium compound is 1:0.1 to 1:10. If the weight of calcium in the calcium compound is less than 0.01 times the weight of water-soluble dietary fiber, sufficient gelation will not occur even if all the calcium compound is dissolved by stomach acid. On the other hand, when the weight of calcium in the calcium compound is 8 times or more relative to the water-soluble dietary fiber, the calcium compound becomes rough and confusing, resulting in decreased palatability.
また、本発明の食品用組成物は呈味性が低いので、本発
明の目的を逸脱しない範囲でいかなる食品にも配合する
ことができる。Furthermore, since the food composition of the present invention has low taste, it can be incorporated into any food without departing from the purpose of the present invention.
次に、本発明の試験例および実施例を示すが、本発明は
これらにより制限されるものではない。Next, test examples and examples of the present invention will be shown, but the present invention is not limited thereto.
試験例1
種々の水溶性食物繊維と種々のカルシウム化合物との混
合物の中性領域および酸性領域でのゲル形成について比
較した。すなわち、アルギン酸ナトリウム、カラギーナ
ン、ペクチン、アラビアガム、グアガム、カルボキシメ
チルセルロースおよびキサンタンガムについてそれぞれ
500■を計り取り蒸留水50111に溶解した後、I
NのNaOH溶液でp)lを7.0とし、さらに蒸留水
を加え100戚とした。この溶液を511!i!づつ試
験管に分取した。Test Example 1 The gel formation of mixtures of various water-soluble dietary fibers and various calcium compounds in a neutral region and an acidic region was compared. That is, 500 ml of each of sodium alginate, carrageenan, pectin, gum arabic, guar gum, carboxymethyl cellulose and xanthan gum was weighed out and dissolved in 50111 of distilled water.
The p)l was adjusted to 7.0 with a NaOH solution of N, and distilled water was further added to adjust the p value to 100. This solution is 511! i! Aliquot them into test tubes.
この分取した溶液に塩化カルシウム、炭酸カルシウム、
クエン酸カルシウム、燐酸水素カルシウム。Calcium chloride, calcium carbonate,
Calcium citrate, calcium hydrogen phosphate.
乳酸カルシウム、第3燐酸カルシウム、卵殻カルシウム
、牛骨カルシウムおよび魚骨カルシウムをカルシウムと
して25■となるよう添加し、溶解ないし懸濁した。こ
の時の溶液の性状を観察し、その結果を表1に示す。さ
らに、この溶液に1/IONの塩酸200μlを加えて
攪拌し、その性状を観察した。結果を表2に示す。表1
および表2に示すごとく、pH7,0では溶液の性状に
変化がなく、塩酸添加時にゲルを形成する組合せは、ア
ルギン酸ナトリウムまたはジェランガムと炭酸カルシウ
ム、第3燐酸カルシウム、卵殻カルシウム、牛骨カルシ
ウムまたは魚骨カルシウムの組合せのみであった。なお
、ペクチンもゲルを形成するが、このゲルは弱いもので
あった。また、第3燐酸カルシウムは牛骨カルシウムと
、炭酸カルシウムは卵殻カルシウムとほぼ同等の組成を
有し、本試験例においてもゲル形成に関して同様の作用
を示すことから、以下の実施例では水溶性食物繊維とし
てはアルギン酸ナトリウムおよびジェランガムを、カル
シウム化合物としては炭酸カルシウムおよび第3燐酸カ
ルシウムを使用することとした。Calcium lactate, tertiary calcium phosphate, eggshell calcium, beef bone calcium and fish bone calcium were added to give a total calcium concentration of 25 μm and dissolved or suspended. The properties of the solution at this time were observed, and the results are shown in Table 1. Further, 200 μl of 1/ION hydrochloric acid was added to this solution, stirred, and its properties were observed. The results are shown in Table 2. Table 1
As shown in Table 2, there is no change in the properties of the solution at pH 7.0, and the combinations that form a gel when hydrochloric acid is added are sodium alginate or gellan gum and calcium carbonate, tribasic calcium phosphate, eggshell calcium, beef bone calcium, or fish. The only combination was bone calcium. Note that pectin also forms a gel, but this gel is weak. In addition, tertiary calcium phosphate has almost the same composition as beef bone calcium, and calcium carbonate has almost the same composition as eggshell calcium, and since they show similar effects regarding gel formation in this test example, water-soluble food Sodium alginate and gellan gum were used as the fibers, and calcium carbonate and tertiary calcium phosphate were used as the calcium compounds.
試験例2
アルギン酸ナトリウムまたはジェランガムと炭酸カルシ
ウムの混合物と先行技術であるカラギナンとカゼインナ
トリウムの混合物について粘度の温度依存性を比較した
。すなわち、5o!Idl容のビーカーを3個用意し、
その1つにはアルギン酸ナトリウム250■と炭酸カル
シウム250■を、2個目にはジェランガム250■と
炭酸カルシウム250■を、残る1つにはカラギナン2
50■とカゼインナトリウム125■をそれぞれ計り取
り蒸留水を加え、60°Cの恒温槽内で加温しながら溶
解し50mとした。この3種類の溶液につぃて60°C
150°C940°C130°C225°C(室温)、
20°c、iooCおよび4°C(冷蔵温度)の各温度
における粘度を測定した。粘度の測定はB型回転粘度計
(東京計器製造所■製)を用いて行った。結果は第1図
に示すごとく、アルギン酸ナトリウムと炭酸カルシウム
の溶液では温度低下に伴う粘度の上昇はほとんど見られ
ず、摂取も容易であった。Test Example 2 The temperature dependence of viscosity was compared between a mixture of sodium alginate or gellan gum and calcium carbonate and a prior art mixture of carrageenan and sodium caseinate. In other words, 5o! Prepare three beakers of Idl capacity,
One of them contains 250μ of sodium alginate and 250μ of calcium carbonate, the second contains 250μ of gellan gum and 250μ of calcium carbonate, and the remaining one contains 250μ of carrageenan.
50 μm and 125 μm of sodium caseinate were weighed out, distilled water was added, and dissolved while heating in a constant temperature bath at 60° C. to make 50 μm. 60°C for these three solutions
150°C940°C130°C225°C (room temperature),
The viscosity was measured at 20°C, iooC and 4°C (refrigeration temperature). The viscosity was measured using a B-type rotational viscometer (manufactured by Tokyo Keiki Seisakusho ■). The results are shown in Figure 1, with the solution of sodium alginate and calcium carbonate, there was almost no increase in viscosity associated with a decrease in temperature, and it was easy to ingest.
実施例1
100all!容のメスフラスコを3本用意し、1木目
にはアルギン酸ナトリウム500■、炭酸カルシウム5
00■およびグルコース10gをメスフラスコに取り蒸
留水を加えて溶解し、100dとした。2木目には、ア
ルギン酸ナトリウム500■およびグルコース10gを
メスフラスコに取り蒸留水を加えて溶解し、100Id
とした。3本口には、グルコース10gをメスフラスコ
に取り蒸留水を加えて溶解し、100dとした。この3
種類の試料の胃内滞留時間を比較すべくラットに投与し
た。ラットはSD系雄性、体重的200gのものを1群
6個体とし、計18個体用いた。Example 1 100all! Prepare three volumetric flasks with a volume of 500 μm and 500 μm of sodium alginate and 5 μm of calcium carbonate in the first grain.
00■ and 10 g of glucose were placed in a volumetric flask and distilled water was added to dissolve them to make 100 d. For the second grain, take 500 Id of sodium alginate and 10 g of glucose into a volumetric flask and add distilled water to dissolve them.
And so. For the third bottle, 10 g of glucose was placed in a volumetric flask and distilled water was added to dissolve it to make 100 d. This 3
Different types of samples were administered to rats in order to compare their retention times in the stomach. A total of 18 SD male rats, 6 rats per group, weighing 200 g were used.
まず、ラットを24時間絶食させ、上記3種類の試料を
体重100g当りldの割合で胃ゾンデにて強制投与し
た。投与30分後、断頭層殺し、腹部を切開して胃の幽
門部および食道をクレンメで閉塞後、胃を摘出した。摘
出した胃の内容物を最終量が10dとなるように蒸留水
で洗い込み試験管に取った。この溶液を300Orpm
で10分間遠心分離し、得られた上清をムタロターゼ・
GOD法でグルコース量を測定し、各試料の胃内残存率
を求めた。結果を第2図に示す。第2図に示されるごと
く、アルギン酸ナトリウム0.5%、炭酸カルシウム0
.5%およびグルコース10%を投与した群は、他の2
群に比して有意に高い残存率を示した。また、アルギン
酸ナトリウム0.5%。First, rats were fasted for 24 hours, and the three types of samples mentioned above were forcibly administered at a rate of 1 d/100 g of body weight using a gastric tube. Thirty minutes after administration, the animal was decapitated, the abdomen was incised, the pylorus of the stomach and the esophagus were obstructed with a cleanser, and the stomach was removed. The contents of the excised stomach were washed with distilled water to a final volume of 10 d and taken into a test tube. This solution was heated to 300 rpm.
Centrifuge for 10 minutes at
The amount of glucose was measured by the GOD method, and the residual rate in the stomach of each sample was determined. The results are shown in Figure 2. As shown in Figure 2, sodium alginate 0.5%, calcium carbonate 0
.. The groups administered 5% and 10% glucose were
The survival rate was significantly higher than that of the other groups. Also, sodium alginate 0.5%.
炭酸カルシウム0.5%およびグルコース10%を投与
した群は、投与した試料が胃内で透明なゲルを形成して
いた。In the group to which 0.5% calcium carbonate and 10% glucose were administered, the administered sample formed a transparent gel in the stomach.
実施例2
10011j!容のメスフラスコを2本用意し、1木目
にはアルギン酸ナトリウム500■、第3燐酸カルシウ
ム500■およびグルコース10gをメスフラスコに取
り蒸留水を加えて溶解し、100dとした。2木目には
、アルギン酸ナトリウム500■およびグルコース10
gをメスフラスコに取り蒸留水を加え溶解し100−と
じた。この2種類の試料の耐糖能改善効果を比較すべく
ラットに投与した。ラットはSD系雄性、体重的200
gのものを1群6個体とし、計12個体用いた。Example 2 10011j! Two volumetric flasks were prepared, and in the first grain, 500 μm of sodium alginate, 500 μm of tertiary calcium phosphate, and 10 g of glucose were placed in the volumetric flasks and distilled water was added to dissolve them to give a total volume of 100 μm. For the second grain, sodium alginate 500■ and glucose 10
g was taken into a volumetric flask, distilled water was added to dissolve it, and the mixture was sealed at 100%. These two types of samples were administered to rats in order to compare their effects on improving glucose tolerance. The rat is an SD male, weight 200.
A total of 12 individuals were used, with 6 individuals per group.
まず、ラットを24時間絶食させ、上記2種類の試料を
体重100g当り1dの割合で胃ゾンデにて強制投与し
た。投与前、投与15分後、投与30分後および投与6
0分後の各時点で尾静脈より血液30μlを採血し、直
ちにグルコースオキシダーゼ法で血糖値を測定した。結
果を第3図に示す。第3図に示されるごとく、アルギン
酸ナトリウム0.5%、第3燐酸カルシウム0.5%お
よびグルコース10%を投与した群は、アルギン酸ナト
リウム0゜5%、およびグルコース10%を投与した群
に比して、投与15分後の血糖値は低値を示し、投与6
0分後ではやや高値を示した。First, rats were fasted for 24 hours, and the two types of samples mentioned above were forcibly administered at a rate of 1 d per 100 g of body weight using a gastric tube. Before administration, 15 minutes after administration, 30 minutes after administration and administration 6
At each time point after 0 minutes, 30 μl of blood was collected from the tail vein, and the blood sugar level was immediately measured using the glucose oxidase method. The results are shown in Figure 3. As shown in Figure 3, the group administered with 0.5% sodium alginate, 0.5% tertiary calcium phosphate and 10% glucose was compared to the group administered with 0.5% sodium alginate and 10% glucose. 15 minutes after administration, the blood sugar level showed a low value.
After 0 minutes, the value was slightly high.
従って、アルギン酸ナトリウム0.5%、第3燐酸カル
シウム0.5%およびグルコース10%を投与した群は
急激な血糖値の上昇を抑え、ゆっくりと糖の吸収を行わ
せる、即ち耐糖能を改善する効果が認められた。Therefore, the group administered with 0.5% sodium alginate, 0.5% tribasic calcium phosphate, and 10% glucose suppressed the rapid rise in blood sugar level and allowed sugar absorption to occur slowly, that is, to improve glucose tolerance. The effect was recognized.
実施例3
100jd!容のメスフラスコを3本用意し、1木目に
はアルギン酸ナトリウム500■および炭酸カルシウム
500■をメスフラスコに取り蒸留水を加えて溶解し、
100dとした。2木目には、アルギン酸ナトリウム5
00■をメスフラスコに取り蒸留水を加えて溶解し、1
00dとした。また、3本口には、アルギン酸ナトリウ
ム500■をメスフラスコに取り蒸留水を加えて溶解し
、100dとしたのち、この溶液を100−容ビーカー
に移し、塩化カルシウム500■を加えゲルを形成させ
た。このゲルをミキサーで破砕し、被検液とした。この
3種類の試料の耐糖能改善効果を比較較すべくラットに
投与した。ラットはSD系雄性、体重的200gのもの
を1群6個体とし、計24個体用いた。Example 3 100jd! Prepare 3 volumetric flasks, put 500 μm of sodium alginate and 500 μm of calcium carbonate into the volumetric flask and add distilled water to dissolve them.
It was set to 100d. On the second grain, sodium alginate 5
Take 00■ in a volumetric flask and add distilled water to dissolve it.
It was set to 00d. In addition, for the third neck, take 500 µm of sodium alginate in a volumetric flask, add distilled water to dissolve it to make 100 d, then transfer this solution to a 100-capacity beaker, add 500 µm of calcium chloride, and form a gel. Ta. This gel was crushed with a mixer and used as a test solution. These three types of samples were administered to rats in order to compare their effects on improving glucose tolerance. A total of 24 SD male rats, 6 rats per group, weighing 200 g were used.
まず、ラットにストレプトシトシンを体重100g当り
55■の割合で尾静脈より注射して、糖尿病モデルラッ
トを作製し、2週間後実験に供した。First, streptocytosine was injected into rats through the tail vein at a rate of 55 μg per 100 g of body weight to prepare diabetic model rats, and 2 weeks later they were used for experiments.
ラットを24時間絶食させ、上記3種類の試料を体重1
00g当りll11の割合で胃ゾンデにて強制投与し、
その直後に10%グルコース溶液1dを胃ゾンデにて強
制投与した。また、対照群には蒸留水を体重100g当
りll11の割合で胃ゾンデにて強制投与し、その直後
に10%グルコース溶液IIdを胃ゾンデにて強制投与
した。投与前、投与15分後、投与30分後、投与60
分後および投与120分後の各時点で尾静脈より血液3
0mを採血し、直ちにグルコースオキシダーゼ法で血糖
値を測定した。結果を第4図に示す。第4図に示される
ごとく、アルギン酸ナトリウム0.5%。Rats were fasted for 24 hours, and the above three types of samples were added to the body weight of 1
Forcibly administered with a gastric tube at a rate of 11/00g,
Immediately thereafter, 1 d of 10% glucose solution was forcibly administered using a stomach tube. In addition, to the control group, distilled water was forcibly administered at a rate of 11 l/100 g of body weight using a stomach probe, and immediately thereafter, a 10% glucose solution IId was forcibly administered using a stomach probe. Before administration, 15 minutes after administration, 30 minutes after administration, 60 minutes after administration
Blood was collected from the tail vein at each time point 3 min and 120 min after administration.
Blood was collected at 0 m, and the blood sugar level was immediately measured using the glucose oxidase method. The results are shown in Figure 4. As shown in Figure 4, sodium alginate 0.5%.
炭酸カルシウム0.5%およびグルコース10%を投与
した群では他の3群に比して、投与15分後の血糖値は
低値を示し、投与60分後ではやや高値を示した。この
ような糖尿病ラットにおいてもアルギン酸ナトリウム0
.5%、炭酸カルシウム0.5%およびグルコース10
%を投与した群では他の2群に比して、急激な血糖値の
上昇を抑えゆっくりと糖の吸収を行わせる、即ち、耐糖
能を改善する効果が認められた。In the group to which 0.5% calcium carbonate and 10% glucose were administered, the blood sugar level showed a lower value 15 minutes after administration, and a slightly higher value 60 minutes after administration, compared to the other three groups. Even in such diabetic rats, sodium alginate 0
.. 5%, calcium carbonate 0.5% and glucose 10
Compared to the other two groups, the group administered % of the drug was found to have the effect of suppressing the rapid rise in blood sugar levels and slowing down sugar absorption, that is, improving glucose tolerance.
以上詳述したごとく、
本発明の食品用組成物は、
水溶性食物繊維と中性領域で不溶性のカルシウム化合物
を含有することにより、摂取後胃内で胃酸と接触した際
ゲルを、形成する。食物の胃内滞留時間は、成分によっ
ても異なるが、食物繊維においてはその粘度が高いほど
胃内滞留時間は長くなる。As detailed above, the food composition of the present invention contains water-soluble dietary fiber and a calcium compound that is insoluble in the neutral region, so that it forms a gel when it comes into contact with gastric acid in the stomach after ingestion. The residence time of food in the stomach varies depending on the ingredients, but the higher the viscosity of dietary fiber, the longer the residence time in the stomach.
従って、本発明の食品用組成物を摂取すれば、摂取時は
低温でも粘度が低く嗜好性に優れている上に胃内ではゲ
ル化し、胃内に長時間滞留するため、効果的に食欲を抑
制することができる。しかも、糖の吸収を遅延させるた
め、耐糖能をも改善する。Therefore, if the food composition of the present invention is ingested, it has a low viscosity and good palatability even at low temperatures, and also gels in the stomach and remains there for a long time, effectively suppressing appetite. Can be suppressed. Moreover, it also improves glucose tolerance by delaying sugar absorption.
さらには、本食品用組成物を摂取することにより、最近
摂取の不足が指摘されている食物繊維とカルシウムの栄
養的な補給も同時に行うことができる。Furthermore, by ingesting this food composition, it is possible to simultaneously provide nutritional supplementation of dietary fiber and calcium, which have recently been pointed out to be insufficient in intake.
また、カルシウムの吸収を促進することが知られている
カゼインホスホペプチドと組み合せることも容易であり
、さらにカルシウムの栄養的な補給効果を高めることが
できる。また、本発明の食品用組成物は食品の加工時に
pHが3.5以下にならないような工程を選べば、水溶
性食物繊維と中性領域で不溶性のカルシウム化合物の反
応が生じないため、液状、粉状、固形状などあらゆる食
品の形態を選択することかでき、かつ水溶性食物繊維と
中性領域で不溶性のカルシウム化合物はいずれも無味無
臭に近いため、様々な味付けか可能であり、本発明の食
品用組成物を継続的に摂取する場合、極めて好都合であ
る。Furthermore, it can be easily combined with casein phosphopeptide, which is known to promote calcium absorption, and can further enhance the nutritional supplementation effect of calcium. In addition, if the food composition of the present invention is selected in a process that does not cause the pH to fall below 3.5 during food processing, the reaction between the water-soluble dietary fiber and the insoluble calcium compound in the neutral region will not occur. You can choose any food form, such as powder, solid, etc., and since both water-soluble dietary fiber and insoluble calcium compounds in the neutral range are almost tasteless and odorless, various flavorings are possible. It is extremely advantageous if the food composition of the invention is taken continuously.
第1図は各種食物繊維含有組成物溶液の温度−粘度相関
図、第2図は動物実験における投与30分後の胃内のグ
ルコースの残存量を示す図、第3図は正常なラットを用
いた試験における血糖値(ラット6匹の平均値)の変化
を示す図、第4図は糖尿病ラットを用いた試験における
血糖値(ラット6匹の平均値)の変化を示す図である。
殿巳
拓
図
(本会9男)
憩
凹
蔚
間
ト偏0
第
図
時
開
障ノFigure 1 is a temperature-viscosity correlation diagram of various dietary fiber-containing composition solutions, Figure 2 is a diagram showing the residual amount of glucose in the stomach 30 minutes after administration in animal experiments, and Figure 3 is a diagram showing the amount of glucose remaining in the stomach 30 minutes after administration in animal experiments. Figure 4 is a diagram showing changes in blood sugar levels (average value of 6 rats) in a test using diabetic rats. Takuzu Tonomi (9th son of the Society) Ikuko Urugma Tobias 0 Diagram Time Opening Obstruction
Claims (5)
化合物を含有する組成物からなり、該水溶性食物繊維と
該カルシウム化合物の水溶液が胃液と接触した際にゲル
状となるような割合であることを特徴とする食品用組成
物。(1) A composition comprising water-soluble dietary fiber and an insoluble calcium compound in a neutral range, in a ratio such that an aqueous solution of the water-soluble dietary fiber and the calcium compound becomes gel-like when it comes into contact with gastric juice. A food composition characterized in that:
る請求項1記載の食品用組成物。(2) The food composition according to claim 1, wherein the water-soluble dietary fiber is alginic acid or a salt thereof.
ルシウム、卵殻カルシウム、牛骨カルシウムおよび魚骨
カルシウムから選ばれた1種または2種以上の組合せで
ある請求項1記載の食品用組成物。(3) The food composition according to claim 1, wherein the calcium compound is one or a combination of two or more selected from calcium carbonate, tertiary calcium phosphate, eggshell calcium, beef bone calcium, and fish bone calcium.
ムとの重量比が1:0.1〜1:10である請求項1記
載の食品用組成物。(4) The food composition according to claim 1, wherein the weight ratio of water-soluble dietary fiber to calcium in the calcium compound is 1:0.1 to 1:10.
ムとの重量比が1:0.5〜1:2である請求項1記載
の食品用組成物。(5) The food composition according to claim 1, wherein the weight ratio of water-soluble dietary fiber to calcium in the calcium compound is 1:0.5 to 1:2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2125544A JP2673992B2 (en) | 1990-05-17 | 1990-05-17 | Food composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2125544A JP2673992B2 (en) | 1990-05-17 | 1990-05-17 | Food composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0423968A true JPH0423968A (en) | 1992-01-28 |
JP2673992B2 JP2673992B2 (en) | 1997-11-05 |
Family
ID=14912827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2125544A Expired - Lifetime JP2673992B2 (en) | 1990-05-17 | 1990-05-17 | Food composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2673992B2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002017734A3 (en) * | 2000-09-01 | 2003-04-24 | Univ Tennessee Res Corp | Materials and methods for the treatment or prevention of obesity |
JP2004002320A (en) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | Liquid matrix causing in-vivo phase transition and liquid oral preparation |
EP1395128A2 (en) † | 2001-05-31 | 2004-03-10 | Abbott Laboratories | Acid controlled viscosity fibre system and uses thereof |
WO2005020719A1 (en) * | 2003-09-03 | 2005-03-10 | Unilever N.V. | Satiety enhancing food compositions |
WO2005020718A1 (en) * | 2003-09-03 | 2005-03-10 | Unilever N.V. | Satiety enhancing food compositions |
US7704979B2 (en) | 2000-09-01 | 2010-04-27 | The University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
JP2014000054A (en) * | 2012-06-20 | 2014-01-09 | Shimadaya Corp | Wheat noodle for preventing rise of blood glucose level after ingestion |
US8889617B2 (en) | 2009-12-18 | 2014-11-18 | Kaneka Corporation | Liquid food composition |
JP2015089357A (en) * | 2013-11-06 | 2015-05-11 | ユニテックフーズ株式会社 | New gelatinizer |
US9192573B2 (en) | 2009-12-18 | 2015-11-24 | Kaneka Corporation | Treatment method using liquid food composition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1931222T3 (en) * | 2005-10-05 | 2012-07-31 | Technostics Ltd | Gelling compositions and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5774072A (en) * | 1980-10-29 | 1982-05-10 | Yamanouchi Pharmaceut Co Ltd | Granule of dietary fiber and its preparation |
JPS6348210A (en) * | 1986-08-19 | 1988-02-29 | Freunt Ind Co Ltd | Easily soluble granule |
JPS63185339A (en) * | 1986-09-01 | 1988-07-30 | Terumo Corp | Composition for food |
-
1990
- 1990-05-17 JP JP2125544A patent/JP2673992B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5774072A (en) * | 1980-10-29 | 1982-05-10 | Yamanouchi Pharmaceut Co Ltd | Granule of dietary fiber and its preparation |
JPS6348210A (en) * | 1986-08-19 | 1988-02-29 | Freunt Ind Co Ltd | Easily soluble granule |
JPS63185339A (en) * | 1986-09-01 | 1988-07-30 | Terumo Corp | Composition for food |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001288707B9 (en) * | 2000-09-01 | 2007-08-30 | University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
WO2002017734A3 (en) * | 2000-09-01 | 2003-04-24 | Univ Tennessee Res Corp | Materials and methods for the treatment or prevention of obesity |
US7704979B2 (en) | 2000-09-01 | 2010-04-27 | The University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
AU2001288707C1 (en) * | 2000-09-01 | 2008-05-29 | University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
US8541392B2 (en) | 2001-05-31 | 2013-09-24 | Abbott Laboratories | Polymer controlled induced viscosity fiber system and uses thereof |
EP1395128A2 (en) † | 2001-05-31 | 2004-03-10 | Abbott Laboratories | Acid controlled viscosity fibre system and uses thereof |
EP1395128B2 (en) † | 2001-05-31 | 2011-07-13 | Abbott Laboratories | Acid controlled viscosity fibre system and uses thereof |
JP2004002320A (en) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | Liquid matrix causing in-vivo phase transition and liquid oral preparation |
WO2005020718A1 (en) * | 2003-09-03 | 2005-03-10 | Unilever N.V. | Satiety enhancing food compositions |
WO2005020719A1 (en) * | 2003-09-03 | 2005-03-10 | Unilever N.V. | Satiety enhancing food compositions |
US8889617B2 (en) | 2009-12-18 | 2014-11-18 | Kaneka Corporation | Liquid food composition |
US9192573B2 (en) | 2009-12-18 | 2015-11-24 | Kaneka Corporation | Treatment method using liquid food composition |
EP3461473A1 (en) | 2009-12-18 | 2019-04-03 | Kaneka Corporation | Liquid food composition being semisolidified in the acidic region |
JP2014000054A (en) * | 2012-06-20 | 2014-01-09 | Shimadaya Corp | Wheat noodle for preventing rise of blood glucose level after ingestion |
JP2015089357A (en) * | 2013-11-06 | 2015-05-11 | ユニテックフーズ株式会社 | New gelatinizer |
Also Published As
Publication number | Publication date |
---|---|
JP2673992B2 (en) | 1997-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101925307B (en) | High energy liquid enteral nutritional composition | |
JP2599400B2 (en) | Formulated liquid nutritional composition for glucose intolerant patients | |
WO2008066308A1 (en) | Food composition for increasing the satiety and satiation | |
CN104642839B (en) | A kind of health-care fish oil jelly and preparation method thereof | |
WO2021104155A1 (en) | Hydrogel tablet for dispelling effect of alcohol and protecting liver, and preparation method therefor and use thereof | |
WO1988001477A1 (en) | Food composition | |
JPH0423968A (en) | Composition for food | |
JPS63287462A (en) | Peptide nutrient agent | |
JP2002034592A (en) | Method for producing protein-zinc readily absorbable in body | |
EP0075594A1 (en) | Glucose polymers and method of producing same | |
JP3720496B2 (en) | Novel pectin and emulsion containing the same | |
JP5383244B2 (en) | Nutritional agent suitable for improving symptoms or nutritional status of cancer patients | |
JPH11332514A (en) | Balanced nutritive food | |
CN111406935A (en) | Carbohydrate component formula food suitable for preoperative taking and having special medical application and application thereof | |
JP2000050819A (en) | Rice gruel | |
JPH0621077B2 (en) | Hematopoietic agent | |
CN115067504B (en) | Special medical food for intestinal tract preparation and preparation method thereof | |
JP2986324B2 (en) | Diet / Diabetic Food | |
EP1037539A1 (en) | Method for accelerating protein digestion rate | |
JP2000189109A (en) | Liquid food | |
JP2002142720A (en) | Nutritional composition | |
JP3165743B2 (en) | Liquid food | |
JP3336340B2 (en) | Rice treated with artificial digestive enzyme and its production method | |
JP2900070B2 (en) | Potassium supplement composition for food and method for producing the same | |
JP2017160177A (en) | Slurry nutritional composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090718 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100718 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term |